- In October 2023, Hitachi, Ltd. delivered its first proton therapy system to the National Cancer Centre Singapore, marking the first proton therapy treatment in Southeast Asia, completed on 11 August 2023. This strategic launch is expected to enhance Hitachi's market presence, drive business revenue, and expand its customer base in the healthcare sector
- In May 2023, Philips expanded its mobile C-arm portfolio with the introduction of Zenition 10, a next-generation system designed to offer enhanced imaging capabilities for intraoperative guidance. This addition strengthens Philips' position in the surgical imaging market, providing healthcare professionals with advanced tools for improved patient outcomes during minimally invasive procedures
- In April 2023, GE HealthCare launched Pixxoscan, a new MRI contrast agent, expanding its portfolio with two leading macrocyclic molecules: Clariscan (gadoteric acid) and Pixxoscan (gadobutrol). This launch aims to offer advanced diagnostic capabilities, improve imaging precision, and enhance patient care, solidifying GE's position in the medical imaging and contrast agent market
- In June 2023, GE HealthCare announced plans to enhance its PET/MR capabilities with AIR technologies, aiming to increase diagnostic precision and simplify treatment evaluations. This development also focuses on improving patient comfort during scans, reinforcing GE's commitment to advancing imaging technologies and enhancing patient care within the growing diagnostic imaging market
- In September 2022, China's National Medical Products Administration (NMPA) approved ViewRay's MRIdian MRI-guided radiation therapy system for sale and use. This approval allows ViewRay to expand its footprint in the Chinese market, offering advanced cancer treatment solutions that integrate MRI and radiation therapy to improve precision and outcomes in cancer care
- In October 2020, Elekta launched the Elekta Harmony linear accelerator (linac), a new cancer treatment system designed to improve precision in radiation therapy. This strategic product introduction helps Elekta expand its cancer care offerings, increase its market share, and drive revenue growth in the rapidly evolving radiation therapy sector
Frequently Asked Questions
The market is segmented based on Global Image-Guided Radiation Therapy Market Segmentation, By Type (4D gating/4D RT, LINAC (Linear Accelerator), Portal Imaging, Soft-Tissue Imaging, Lung MRI, Simplifying Cardiac MRI, Simplifying MRI-Conditional Implant Scans, Silent MRI Scanning, and Others), Application (Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, and Others), Procedure (Intensity-modulation radiation therapy, 3D Conformal Radiation therapy, Stereotactic therapy, Proton beam therapy, Particle therapy), Devices (X-Ray CT, MRI, PET, and Others), End-Users (Hospitals, Smart Cancer Centers, Research Institutes, Independent Radiotherapy Centers, and Others) – Industry Trends and Forecast to 2032
.
The Global Image Guided Radiation Therapy Market size was valued at USD 2.11 USD Billion in 2024.
The Global Image Guided Radiation Therapy Market is projected to grow at a CAGR of 11.05% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
